Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic

The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the abs...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Camille E., Rimland, Casey A., Bell, Griffin J., Kim, Min K., Hedrick, Tanner, Marx, Ashley, Bramson, Brian, Swygard, Heidi, Napravnik, Sonia, Schmitz, John L., Carson, Shannon S., Fischer, William A., Eron, Joseph J., Gay, Cynthia L., Parr, Jonathan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493269/
https://www.ncbi.nlm.nih.gov/pubmed/34626958
http://dx.doi.org/10.1016/j.hjdsi.2021.100581
Descripción
Sumario:The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.

Ejemplares similares